Florida Biologix® Announces Manufacturing Agreement with Altor BioScience
June 28, 2011 Alachua, FL. Altor BioScience and Florida Biologix team up to move an important interleukin-15 (IL-15)-based immunotherapeutic, ALT-803, to the clinic as a novel cancer therapy. ALT-803, a proprietary IL-15 super agonist/IL-15Rα-Fc fusion complex, has demonstrated impressive anti-tumor activities in various pre-clinical cancer models and could potentially make a life-changing difference for patients with solid and hematological tumors.
